Spark Therapeutics Gets a Buy Rating from William Blair

William Blair analyst Raju Prasad maintained a Buy rating on Spark Therapeutics (NASDAQ: ONCE) today. The company’s shares opened today at $72.71.

Prasad observed:

“We view this guidance as in line with our expectations and believe that data in the seven treated patients disclosed at ASH will likely provide duration data between 9 and 18 months post- infusion in addition to earlier data in additionally treated patients since this update. From speaking with key opinion leaders, there is some belief that the steady-state range of factor VIII levels may occur later than with factor IX (potentially in the 28- to 32-week range), and if so, the data could show a clinical benefit similar to the SPK-9001 data as determined by a significant reduction in annualized bleeding rate and factor usage.”

According to TipRanks.com, Prasad is a 4-star analyst with an average return of 25.0% and a 61.1% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Audentes Therapeutics, and PTC Therapeutics.

Currently, the analyst consensus on Spark Therapeutics is Moderate Buy and the average price target is $78.25, representing a 7.6% upside.

In a report issued on April 30, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $103 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $91.75 and a one-year low of $41.06. Currently, Spark Therapeutics has an average volume of 633.5K.

Based on the recent corporate insider activity of 46 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Spark Therapeutics, Inc. engages in the research, development, and commercialization of gene therapies. Its product portfolio intends to treat inherited retinal sickness, liver-mediated, and neurodegenerative diseases. The company was founded by Jean Bennett, Beverly Davidson, Katherine A. High, Jeffrey D. Marrazzo, J.